ECDC - Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice

ECDC - Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice

European Centre for Disease Prevention and Control

This document outlines the key challenges that countries are facing with the COVID-19 vaccination rollout and lessons learned to mitigate these challenges.

ECDC - Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination

ECDC - Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination

European Centre for Disease Prevention and ControlMore than one year into the SARS-CoV-2 pandemic, over 120 million people have been infected with the virus across more than 200 countries. Reinfections following natural infections with the same...
AMP - The Impact of the COVID-19 Pandemic on Children’s Health in Portugal: The Parental Perspective

AMP - The Impact of the COVID-19 Pandemic on Children’s Health in Portugal: The Parental Perspective

Acta Médica PortuguesaThe COVID-19 pandemic poses unprecedented challenges for healthcare services and has led to changes in the usage pattern of the pediatric population. We aimed to describe the impact of COVID-19 on children’s health,...
JAMA - Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted

JAMA - Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted

JAMA NETWORK

The results do not support routine empirical use of intermediate-dose prophylactic anticoagulation in unselected patients with COVID-19 admitted to the ICU.

AMP - Abordagem da Cefaleia no Doente com COVID-19

AMP - Abordagem da Cefaleia no Doente com COVID-19

Acta Médica PortuguesaHeadache is one of the most common neurological symptoms of COVID-19. It has an estimated prevalence of 6% to 71% with most studies reporting 6% to 21%. It often appears simultaneously with other COVID-19 symptoms, is...
JAMA - Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19

JAMA - Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19

JAMA NETWORK

This study provides clinical status of a cohort of patients 4 months after hospitalization for COVID-19, but further research is needed to understand longer-term outcomes.

ECDC - Introducing a coherent European framework for tuning COVID-19 response measures

ECDC - Introducing a coherent European framework for tuning COVID-19 response measures

European Centre for Disease Prevention and ControlThis document describes the development of a coherent, yet non-prescriptive framework for tuning COVID-19 response measures in the European Union and European Economic Area (EU/EEA). Its aim is to...
ECDC - Considerations on the use of self-tests for COVID-19 in the EU/EEA

ECDC - Considerations on the use of self-tests for COVID-19 in the EU/EEA

European Centre for Disease Prevention and ControlRapid antigen detection tests (RADTs) that can be used as self-tests to detect SARS-CoV-2 are becoming available in the European Union/European Economic Area (EU/EEA). These tests require...
ECDC - Guidance for COVID-19 quarantine and testing of travellers

ECDC - Guidance for COVID-19 quarantine and testing of travellers

European Centre for Disease Prevention and ControlTravel measures, such as quarantine and testing of travellers, are designed to reduce the likelihood of SARS-CoV2 transmission prior to, during, and after travel. This document summarises the...
JAMA - SARS-CoV-2 Vaccines

JAMA - SARS-CoV-2 Vaccines

JAMA NETWORKShortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with...
JAMA - Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19A Systematic Review and Meta-analysis

JAMA - Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19A Systematic Review and Meta-analysis

JAMA NETWORKIn a meta-analysis of 4 peer-reviewed and published randomized clinical trials including 1060 patients with COVID-19 treated with convalescent plasma vs control, the risk ratio for mortality was 0.93 and after the addition of 6...
NEJM - BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

NEJM - BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

The New England Journal of MedicineAs mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled...
JAMA - Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

JAMA - Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

JAMA NETWORKHow do the characteristics and outcomes of children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compare with severe coronavirus disease 2019 (COVID-19)?
CDC - Operating schools during COVID-19: CDC's Considerations

CDC - Operating schools during COVID-19: CDC's Considerations

Centre for Disease Prevention and ControlAs communities in the United States consider how to safely re-open K-12 school buildings for in-person learning and activities and keep them open, CDC offers updated considerations for mitigation...
ECDC - Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA

ECDC - Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA

European Centre for Disease Prevention and ControlECDC’s rapid risk assessment on the spread of new SARS-CoV-2 variants of concern in the EU/EEA, published on 21 January 2021, concludes that the risk associated with the introduction and community...
135678910Último
Eventos
«setembro de 2023»
segterquaquisexsábdom
28293031123
45678910
11121314151617
18192021222324
2526272829301
2345678
Categorias

Categorias

Arquivo de Notícias

Arquivo